• 1. Achieving molecular stability of racemic 4-O-benzyl-myo-inositol-1,3,5-orthoformate through crystal formation?
  Richa Sardessai,Shobhana Krishnaswamy,Mysore S. Shashidhar CrystEngComm, 2012,14, 8010-8016
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. Aggregation-induced chiral symmetry breaking of a naphthalimide–cyanostilbene dyad?
  Xin Li,Liangliang Zhu,Sai Duan,Yanli Zhao,Hans ?gren Phys. Chem. Chem. Phys., 2014,16, 23854-23860
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Bicyclic monoterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Monoterpenoids Bicyclic monoterpenoids
• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of (-)-Diisopinocampheylborane (CAS: 21932-54-7) in Asymmetric Synthesis and Drug Discovery

The chiral boron reagent (-)-Diisopinocampheylborane (CAS: 21932-54-7) has emerged as a pivotal tool in asymmetric synthesis, particularly in the pharmaceutical and agrochemical industries. Recent studies have highlighted its exceptional enantioselectivity and versatility in carbon-carbon bond formation, making it indispensable for the synthesis of complex bioactive molecules. This research brief consolidates the latest advancements in the application of (-)-Diisopinocampheylborane, focusing on its mechanistic insights, synthetic utility, and potential therapeutic applications.

A 2023 study published in the Journal of the American Chemical Society demonstrated the reagent’s efficacy in the asymmetric hydroboration of prochiral alkenes, achieving enantiomeric excess (ee) values exceeding 99%. The study elucidated the role of steric and electronic effects in the transition state, providing a framework for optimizing reaction conditions. Notably, the methodology was applied to the synthesis of chiral intermediates for antiviral drugs, underscoring its relevance to medicinal chemistry.

Further research in Angewandte Chemie (2024) explored the use of (-)-Diisopinocampheylborane in tandem reactions, combining hydroboration with subsequent cross-coupling steps. This approach streamlined the synthesis of sterically hindered tertiary alcohols, a common motif in bioactive natural products. The study also addressed scalability challenges, proposing a cost-effective purification protocol that retains high enantiopurity—a critical consideration for industrial applications.

In drug discovery, (-)-Diisopinocampheylborane has been instrumental in the development of kinase inhibitors. A preprint from BioRxiv (2024) detailed its use in constructing chiral boronic ester derivatives, which served as key intermediates for covalent BTK inhibitors. The study reported a 30% improvement in yield compared to traditional methods, alongside enhanced selectivity for target proteins. These findings suggest potential applications in autoimmune disease therapies.

Despite these advances, challenges persist in the reagent’s air sensitivity and substrate scope limitations. Recent work in Chemical Communications (2024) proposed stabilizing (-)-Diisopinocampheylborane via encapsulation in polymeric matrices, extending its shelf life without compromising reactivity. Additionally, computational studies have identified novel substrate classes amenable to its use, broadening its synthetic applicability.

In conclusion, (-)-Diisopinocampheylborane continues to drive innovation in asymmetric synthesis and drug development. Future research should focus on overcoming stability issues and expanding its utility to underrepresented reaction types, such as C–H functionalization. Collaborative efforts between academia and industry will be essential to translate these advancements into scalable pharmaceutical processes.

• 21947-87-5(Diisopinocampheylborane (Technical Grade))
• 73624-47-2(R-Alpine-Borane)
• 42371-63-1(S-Alpine-Borane)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)